BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fallowfield JA, Kendall TJ, Iredale JP. Reversal of fibrosis: no longer a pipe dream? Clin Liver Dis. 2006;10:481-497, viii. [PMID: 17162224 DOI: 10.1016/j.cld.2006.08.022] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
Number Citing Articles
1 Abdel Fattah NS, Ahmed NS. Evidence of intra-hepatic vascular proliferation remodeling early after cure in experimental schistosomiasis mansoni: An immunohistochemical descriptive study. Experimental Parasitology 2012;130:58-62. [DOI: 10.1016/j.exppara.2011.09.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
2 Rashid ST, Humphries JD, Byron A, Dhar A, Askari JA, Selley JN, Knight D, Goldin RD, Thursz M, Humphries MJ. Proteomic analysis of extracellular matrix from the hepatic stellate cell line LX-2 identifies CYR61 and Wnt-5a as novel constituents of fibrotic liver. J Proteome Res. 2012;11:4052-4064. [PMID: 22694338 DOI: 10.1021/pr3000927] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 5.9] [Reference Citation Analysis]
3 Ismail MH, Pinzani M. Reversal of liver fibrosis. Saudi J Gastroenterol. 2009;15:72-79. [PMID: 19568569 DOI: 10.4103/1319-3767.45072] [Cited by in Crossref: 62] [Cited by in F6Publishing: 66] [Article Influence: 5.2] [Reference Citation Analysis]
4 Yang ZX, Liang HY, Hu XX, Huang YQ, Ding Y, Yang S, Zeng MS, Rao SX. Feasibility of histogram analysis of susceptibility-weighted MRI for staging of liver fibrosis. Diagn Interv Radiol 2016;22:301-7. [PMID: 27113421 DOI: 10.5152/dir.2016.15284] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
5 da Costa Souza P, Dondo PS, Souza G, Lopes D, Moscardi M, de Miranda Martinho V, de Mattos Lourenço RD, Prieto T, Balancin ML, Assato AK, Teodoro WR, Rodrigues S, Lima M, Castellano MV, Coletta E, Parra ER, Capelozzi VL. Comprehensive analysis of immune, extracellular matrices and pathogens profile in lung granulomatosis of unexplained etiology. Hum Pathol 2018;75:104-15. [PMID: 29410258 DOI: 10.1016/j.humpath.2018.01.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
6 Elsakkar MG, Eissa MM, Hewedy WA, Nassra RM, Elatrebi SF. Sodium valproate, a histone deacetylase inhibitor, with praziquantel ameliorates Schistosoma mansoni-induced liver fibrosis in mice. Life Sci 2016;162:95-101. [PMID: 27528511 DOI: 10.1016/j.lfs.2016.08.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
7 van Dijk F, Hazelhoff CM, Post E, Prins GGH, Rombouts K, Poelstra K, Olinga P, Beljaars L. Design of a Gene Panel to Expose the Versatile Role of Hepatic Stellate Cells in Human Liver Fibrosis. Pharmaceutics 2020;12:E278. [PMID: 32244897 DOI: 10.3390/pharmaceutics12030278] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Ismail MH, Pinzani M. Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies. Hepat Med. 2011;3:69-80. [PMID: 24367223 DOI: 10.2147/hmer.s9051] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
9 Moles A, Sanchez AM, Banks PS, Murphy LB, Luli S, Borthwick L, Fisher A, O'Reilly S, van Laar JM, White SA, Perkins ND, Burt AD, Mann DA, Oakley F. Inhibition of RelA-Ser536 phosphorylation by a competing peptide reduces mouse liver fibrosis without blocking the innate immune response. Hepatology 2013;57:817-28. [PMID: 22996371 DOI: 10.1002/hep.26068] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
10 Berres ML, Koenen RR, Rueland A, Zaldivar MM, Heinrichs D, Sahin H, Schmitz P, Streetz KL, Berg T, Gassler N, Weiskirchen R, Proudfoot A, Weber C, Trautwein C, Wasmuth HE. Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. J Clin Invest 2010;120:4129-40. [PMID: 20978355 DOI: 10.1172/JCI41732] [Cited by in Crossref: 151] [Cited by in F6Publishing: 89] [Article Influence: 13.7] [Reference Citation Analysis]
11 Snowdon VK, Fallowfield JA. Models and mechanisms of fibrosis resolution. Alcohol Clin Exp Res. 2011;35:794-799. [PMID: 21284668 DOI: 10.1111/j.1530-0277.2010.01400.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
12 Fallowfield J, Hayes P. Pathogenesis and treatment of hepatic fibrosis: is cirrhosis reversible? Clin Med (Lond) 2011;11:179-83. [PMID: 21526707 DOI: 10.7861/clinmedicine.11-2-179] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
13 Hoan NX, Tong HV, Song LH, Meyer CG, Velavan TP. Vitamin D deficiency and hepatitis viruses-associated liver diseases: A literature review. World J Gastroenterol 2018; 24(4): 445-460 [PMID: 29398866 DOI: 10.3748/wjg.v24.i4.445] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
14 Gabr SA, Alghadir AH, Sherif YE, Ghfar AA. Hydroxyproline as a Biomarker in Liver Disease. In: Patel VB, Preedy VR, editors. Biomarkers in Liver Disease. Dordrecht: Springer Netherlands; 2017. pp. 471-91. [DOI: 10.1007/978-94-007-7675-3_26] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Furtado KS, Polletini J, Dias MC, Rodrigues MA, Barbisan LF. Prevention of rat liver fibrosis and carcinogenesis by coffee and caffeine. Food Chem Toxicol 2014;64:20-6. [PMID: 24275088 DOI: 10.1016/j.fct.2013.11.011] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
16 Polasek M, Fuchs BC, Uppal R, Schühle DT, Alford JK, Loving GS, Yamada S, Wei L, Lauwers GY, Guimaraes AR, Tanabe KK, Caravan P. Molecular MR imaging of liver fibrosis: a feasibility study using rat and mouse models. J Hepatol 2012;57:549-55. [PMID: 22634342 DOI: 10.1016/j.jhep.2012.04.035] [Cited by in Crossref: 74] [Cited by in F6Publishing: 67] [Article Influence: 8.2] [Reference Citation Analysis]
17 Artaza JN, Norris KC. Vitamin D reduces the expression of collagen and key profibrotic factors by inducing an antifibrotic phenotype in mesenchymal multipotent cells. J Endocrinol. 2009;200:207-221. [PMID: 19036760 DOI: 10.1677/joe-08-0241] [Cited by in Crossref: 101] [Cited by in F6Publishing: 55] [Article Influence: 7.8] [Reference Citation Analysis]
18 Farrar CT, DePeralta DK, Day H, Rietz TA, Wei L, Lauwers GY, Keil B, Subramaniam A, Sinskey AJ, Tanabe KK, Fuchs BC, Caravan P. 3D molecular MR imaging of liver fibrosis and response to rapamycin therapy in a bile duct ligation rat model. J Hepatol 2015;63:689-96. [PMID: 26022693 DOI: 10.1016/j.jhep.2015.04.029] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 7.2] [Reference Citation Analysis]
19 Sato M, Hwang DM, Guan Z, Yeung JC, Anraku M, Wagnetz D, Hirayama S, Waddell TK, Liu M, Keshavjee S. Regression of allograft airway fibrosis: the role of MMP-dependent tissue remodeling in obliterative bronchiolitis after lung transplantation. Am J Pathol 2011;179:1287-300. [PMID: 21763265 DOI: 10.1016/j.ajpath.2011.05.032] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
20 Hwang SY, Park SY, Hong JY, Lee SY, Shin JH, Na Y, Sohn MH, Yoon HG, Kwon Y. Field-based rational design of p300 histone acetyltransferase inhibitor and systematic evaluation as an anti-fibrotic agent. Chem Commun (Camb) 2020;56:9795-8. [PMID: 32701101 DOI: 10.1039/d0cc03553j] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Wells RG. Liver Fibrosis: Challenges of the New Era. Gastroenterology 2009;136:387-8. [DOI: 10.1053/j.gastro.2008.12.028] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
22 Gabr SA, Alghadir AH, Sherif YE, Ghfar AA. Hydroxyproline as a Biomarker in Liver Disease. In: Preedy VR, editor. Biomarkers in Liver Disease. Dordrecht: Springer Netherlands; 2016. pp. 1-21. [DOI: 10.1007/978-94-007-7742-2_26-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
23 Zeisberg M, Kalluri R. Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis. Am J Physiol Cell Physiol 2013;304:C216-25. [PMID: 23255577 DOI: 10.1152/ajpcell.00328.2012] [Cited by in Crossref: 269] [Cited by in F6Publishing: 246] [Article Influence: 29.9] [Reference Citation Analysis]
24 Yang Y, Wang H, Lv X, Wang Q, Zhao H, Yang F, Yang Y, Li J. Involvement of cAMP-PKA pathway in adenosine A1 and A2A receptor-mediated regulation of acetaldehyde-induced activation of HSCs. Biochimie 2015;115:59-70. [DOI: 10.1016/j.biochi.2015.04.019] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
25 Sukalingam K, Ganesan K, Xu B. Protective Effect of Aqueous Extract from the Leaves of Justicia tranquebariesis against Thioacetamide-Induced Oxidative Stress and Hepatic Fibrosis in Rats. Antioxidants (Basel). 2018;7. [PMID: 29932107 DOI: 10.3390/antiox7070078] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
26 Motola DL, Caravan P, Chung RT, Fuchs BC. Noninvasive Biomarkers of Liver Fibrosis: Clinical Applications and Future Directions. Curr Pathobiol Rep 2014;2:245-56. [PMID: 25396099 DOI: 10.1007/s40139-014-0061-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
27 Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214:199-210. [PMID: 18161745 DOI: 10.1002/path.2277] [Cited by in Crossref: 2468] [Cited by in F6Publishing: 2334] [Article Influence: 189.8] [Reference Citation Analysis]
28 Frohlich J, Vinciguerra M. Candidate rejuvenating factor GDF11 and tissue fibrosis: friend or foe? Geroscience 2020;42:1475-98. [PMID: 33025411 DOI: 10.1007/s11357-020-00279-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
29 Rychik J, Veldtman G, Rand E, Russo P, Rome JJ, Krok K, Goldberg DJ, Cahill AM, Wells RG. The precarious state of the liver after a Fontan operation: summary of a multidisciplinary symposium. Pediatr Cardiol 2012;33:1001-12. [PMID: 22534759 DOI: 10.1007/s00246-012-0315-7] [Cited by in Crossref: 206] [Cited by in F6Publishing: 163] [Article Influence: 22.9] [Reference Citation Analysis]
30 Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest. 2007;117:524-529. [PMID: 17332879 DOI: 10.1172/jci31487] [Cited by in Crossref: 943] [Cited by in F6Publishing: 528] [Article Influence: 67.4] [Reference Citation Analysis]
31 Farrar CT, Gale EM, Kennan R, Ramsay I, Masia R, Arora G, Looby K, Wei L, Kalpathy-Cramer J, Bunzel MM, Zhang C, Zhu Y, Akiyama TE, Klimas M, Pinto S, Diyabalanage H, Tanabe KK, Humblet V, Fuchs BC, Caravan P. CM-101: Type I Collagen-targeted MR Imaging Probe for Detection of Liver Fibrosis. Radiology 2018;287:581-9. [PMID: 29156148 DOI: 10.1148/radiol.2017170595] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
32 Ismail MH, Pinzani M. Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies. Hepat Med. 2011;3:69-80. [PMID: 24367223 DOI: 10.2147/hmer.s905] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Wang J, Shin J, Son J, Cho J, Son C. Antifibrotic effects of CGX, a traditional herbal formula, and its mechanisms in rats. Journal of Ethnopharmacology 2010;127:534-42. [DOI: 10.1016/j.jep.2009.10.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]